New Century Financial Group LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

New Century Financial Group LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,239 shares of the medical device company’s stock, valued at approximately $311,000.

A number of other hedge funds have also made changes to their positions in DXCM. Stableford Capital II LLC grew its stake in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after buying an additional 88 shares during the last quarter. D Orazio & Associates Inc. grew its position in DexCom by 0.8% during the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after acquiring an additional 93 shares during the last quarter. Gulf International Bank UK Ltd increased its holdings in DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in DexCom by 10.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after purchasing an additional 98 shares during the last quarter. Finally, Harbor Investment Advisory LLC boosted its stake in DexCom by 13.1% in the first quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. UBS Group raised their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Redburn Atlantic began coverage on shares of DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Canaccord Genuity Group raised their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Finally, Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.33.

DexCom Trading Down 1.4 %

NASDAQ DXCM opened at $110.91 on Friday. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The stock has a 50-day simple moving average of $121.24 and a 200 day simple moving average of $125.37. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $44.11 billion, a PE ratio of 71.56, a P/E/G ratio of 2.71 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 49,633 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the transaction, the chief executive officer now owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 49,633 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,735 shares of company stock valued at $7,619,347. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.